GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (NAS:BRTX) » Definitions » Altman Z2-Score

BioRestorative Therapies (BioRestorative Therapies) Altman Z2-Score : -34.10 (As of May. 26, 2024)


View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

BioRestorative Therapies has a Altman Z2-Score of -34.10, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for BioRestorative Therapies's Altman Z2-Score or its related term are showing as below:

BRTX' s Altman Z2-Score Range Over the Past 10 Years
Min: -280.34   Med: -99.85   Max: 0.45
Current: -34.1

During the past 13 years, BioRestorative Therapies's highest Altman Z2-Score was 0.45. The lowest was -280.34. And the median was -99.85.


BioRestorative Therapies Altman Z2-Score Historical Data

The historical data trend for BioRestorative Therapies's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioRestorative Therapies Altman Z2-Score Chart

BioRestorative Therapies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -280.34 -79.27 0.45 -4.39 -34.10

BioRestorative Therapies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.39 -16.31 -28.39 -27.21 -34.10

Competitive Comparison of BioRestorative Therapies's Altman Z2-Score

For the Biotechnology subindustry, BioRestorative Therapies's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioRestorative Therapies's Altman Z2-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's Altman Z2-Score falls into.



BioRestorative Therapies Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

BioRestorative Therapies's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.8189+3.26*-13.2458+6.72*-1.143+1.05*10.8504
=-34.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $12.61 Mil.
Total Current Assets was $11.39 Mil.
Total Current Liabilities was $1.06 Mil.
Retained Earnings was $-167.06 Mil.
Pre-Tax Income was -2.825 + -2.925 + -2.981 + -5.684 = $-14.42 Mil.
Interest Expense was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Liabilities was $1.06 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(11.391 - 1.063)/12.612
=0.8189

X2=Retained Earnings/Total Assets
=-167.056/12.612
=-13.2458

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-14.415 - 0)/12.612
=-1.143

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(11.548 - 0.014)/1.063
=10.8504

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

BioRestorative Therapies has a Altman Z2-Score of -34.10 indicating it is in Distress Zones.


BioRestorative Therapies  (NAS:BRTX) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


BioRestorative Therapies Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of BioRestorative Therapies's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


BioRestorative Therapies (BioRestorative Therapies) Business Description

Traded in Other Exchanges
Address
40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Executives
Dale Broadrick 10 percent owner 3003 BRICK CHURCH PIKE, NASHVILLE TN 37207
Lance Alstodt director, 10 percent owner, officer: President, CEO, COB BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Francisco Silva director, 10 percent owner, officer: VP of Research and Development STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Robert Eugene Kristal officer: Chief Financial Officer 4719 COLE AVENUE, DALLAS TX 75205
Patrick F. Williams director C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
David A Rosa director 10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Nickolay V. Kukekov director 4524 WESTWAY AVE, DALLAS TX 75205
Mark Weinreb director, 10 percent owner, officer: CEO and Chairman of the Board STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Paul Jude Tonna director 69 CHICHESTER ROAD, HUNTINGTON NY 11743
A. Jeffrey Radov director 8 WALWORTH AVENUE, SCARSDALE NY 10583
Robert Paccasassi officer: VP, Quality and Compliance C/O BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Robert B Catell director 62 OSBORNE ROAD, GARDEN CITY NY 11530
Adam D. Bergstein officer: SVP, Planning and Business Dev 167 HAZEL AVENUE, GLENCOE IL 60022
John M Desmarais director 230 PARK AVENUE, NEW YORK NY 10169
Westbury Trust 10 percent owner VICTORIA HALL, 11 VICTORIA STREET, P.O. BOX HM 1065, HAMILTON D0 00000

BioRestorative Therapies (BioRestorative Therapies) Headlines

From GuruFocus